Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers

ConditionsEndometrial Clear Cell Adenocarcinoma Endometrial Dedifferentiated Carcinoma Endometrial Mucinous Adenocarcinoma Endometrial Serous Adenocarcinoma Malignant Uterine Neoplasm Uterine Corpus Carcinosarcoma

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexFemale

Age18+

SponsorM.D. Anderson Cancer Center

About this trial

This study is to find out how well liquid biopsies work as a non-invasive alternative to other methods of finding cancer cells (such as a tissue biopsy) in patients with endometrial cancer. A liquid biopsy is a blood test that may be able to find cancer cells. Collecting and storing samples of blood and tissue from patients with endometrial cancer to study in the laboratory may help doctors learn how the cells in the blood may change during treatment for uterine cancer.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Women age 18 years and older

Histologic diagnosis of endometrial cancer

Candidate for primary surgical treatment or has recently had prior primary surgery

Willing and able to provide informed consent

Disqualifiers

None

Trial population

Patients with diagnosis of uterine cancer

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Biospecimen Collection
Procedure/Surgery
Undergo collection of blood and tissue samples
Liquid Biopsy
Procedure/Surgery
Undergo liquid biopsy
Pap Smear
Other intervention
Undergo Pap smear

Treatment groups

1,000 Participants

are divided into 1 treatment group

Group A: Observational (biospecimen collection, Pap smear)3 interventions

Trial outcomes

Primary outcomes

Proportion of circulating cell free deoxyribonucleic acid (ccfDNA) mutations

The proportion of ccfDNA mutations determined by liquid biopsy will be calculated along with 95% confidence intervals, and comparison between treatment time points will be performed.

Time frame

through study completion, an average of 1 year

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

M.D. Anderson Cancer Center

Lead sponsor

Source ClinicalTrials.gov

Apply now